Cara Therapeutics, Inc.

CARA

US1407551092

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
0.7304 ^USD	+10.50%		+2.87%	-1.70%

Mar. 22	Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	CI
Mar. 06	Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	MT

Cara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021

March 01, 2022 at 04:01 pm EST

Cara Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported revenue was USD 0.821 million compared to USD 112.09 million a year ago. Net loss was USD 33.38 million compared to net income of USD 78.91 million a year ago.

Basic loss per share from continuing operations was USD 0.63 compared to basic earnings per share from continuing operations of USD 1.6 a year ago. Diluted loss per share from continuing operations was USD 0.63 compared to diluted earnings per share from continuing operations of USD 1.59 a year ago.

Latest news about Cara Therapeutics, Inc.

Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	Mar. 22	CI
Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	Mar. 06	MT
Transcript : Cara Therapeutics, Inc., Q4 2023 Earnings Call, Mar 04, 2024	Mar. 04
Cara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 04	CI
Earnings Flash (CARA) CARA THERAPEUTICS Reports Q4 Revenue $3M, vs. Street Est of $9.1M	Mar. 04	MT
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Cara Therapeutics to Cut Workforce Up to 50%, Halt Work on Chronic Kidney Disease; Chief Scientific Officer to Exit	Jan. 22	MT
Transcript : Cara Therapeutics, Inc. - Special Call	Jan. 22
Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program	Jan. 22	CI
Cara Therapeutics, Inc. Announces Frédérique Menzaghi Departs as Chief Scientific Officer and SVP of Research & Development, Effective February 2, 2024	Jan. 22	CI
HC Wainwright Adjusts Price Target on Cara Therapeutics to $2.50 From $7, Keeps Buy Rating	Dec. 19	MT
Top Midday Decliners	Dec. 18	MT
Needham Adjusts Price Target on Cara Therapeutics to $6 From $22, Maintains Buy Rating	Dec. 18	MT
Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis	Dec. 18	CI
Cara Therapeutics, Inc.(NasdaqGM:CARA) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Kissei and Maruishi Debut Injection for Dialysis-Related Itching	Dec. 12	MT
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Piper Sandler Downgrades Cara Therapeutics to Neutral From Overweight, Cuts Price Target to $1 From $12	Nov. 14	MT
Cara Therapeutics Q3 Loss Widens, Revenue Drops	Nov. 13	MT
Transcript : Cara Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Earnings Flash (CARA) CARA THERAPEUTICS Posts Q3 Revenue $4.9M, vs. Street Est of $9.9M	Nov. 13	MT
Cara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
HC Wainwright Adjusts Price Target on Cara Therapeutics to $7 From $15, Keeps Buy Rating	23-10-19	MT
Cara Therapeutics Says Partner Receives Approval of Korsuva Injection to Treat Pruritus in Hemodialysis Patients in Japan	23-09-25	MT
Transcript : Cara Therapeutics, Inc., Q2 2023 Earnings Call, Aug 07, 2023	23-08-07

Chart Cara Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Sector

Pharmaceuticals

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Cara Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7304 USD

Average target price

5.12 USD

Spread / Average Target

+600.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CARA THERAPEUTICS, INC.	-1.70%	39.93M
CSL LIMITED	-2.68%	85.68B
SAMSUNG BIOLOGICS CO.,LTD.	+5.53%	41.4B
BIOGEN INC.	-24.99%	28.22B
UCB	+55.45%	24.64B
BIOMARIN PHARMACEUTICAL INC.	-7.19%	16.98B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-34.20%	13.29B
INCYTE CORPORATION	-17.31%	11.66B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.43%	11.65B
SWEDISH ORPHAN BIOVITRUM AB	-1.65%	8.18B

Biopharmaceuticals